Form 4: Puma Biotechnology Director Jay Moyes Boosts Stake with 27,000 RSU Grant

Puma Biotechnology, Inc. Director Jay M. Moyes acquired 27,000 shares of common stock through a Restricted Stock Unit grant on June 11, 2025, increasing his beneficial ownership to 75,322 shares.

Summary

• Jay M. Moyes, a Director of Puma Biotechnology, Inc. (PBYI), acquired 27,000 shares of common stock.
• The transaction occurred on June 11, 2025, and was reported via a Form 4 filing on June 13, 2025.
• The acquisition was a grant of Restricted Stock Units (RSUs) at a price of $0 per share.
• Following this transaction, Mr. Moyes beneficially owns a total of 75,322 shares of Puma Biotechnology common stock.
• The 27,000 RSUs are set to vest on the earlier of the one-year anniversary of the grant date or the date of the annual shareholder meeting following the grant date, contingent on Mr. Moyes' continued service with the Issuer.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director, particularly through an RSU grant, generally indicates confidence in the company's future prospects and aligns management's interests with shareholders, which is a positive signal.

Positives

• The acquisition of shares by a director, particularly through an RSU grant, signals continued confidence in the company's future prospects.
• The grant of Restricted Stock Units aligns the director's long-term financial interests directly with those of the shareholders, as vesting is tied to continued service and potential stock appreciation.

Risks

• The vesting of the 27,000 Restricted Stock Units is contingent upon Jay M. Moyes' continued service with Puma Biotechnology, Inc., meaning the shares are not immediately and unconditionally owned.

Future Outlook

The 27,000 Restricted Stock Units granted to Director Jay M. Moyes are scheduled to vest on the earlier of the one-year anniversary of the grant date (June 11, 2026) or the date of the annual shareholder meeting following the grant date, subject to his continued service with the company.

Industry Context

This Form 4 filing details a specific insider transaction by a director of Puma Biotechnology, Inc. and does not provide broader industry context or trends. Such equity grants are a common practice across various industries for executive and director compensation.

Corporate Governance

Related Party Transactions

• The grant of 27,000 Restricted Stock Units to Director Jay M. Moyes constitutes a related party transaction, as it involves compensation from the issuer to a member of its board of directors.

Stakeholder Impact

• Shareholders: The transaction increases insider ownership, potentially signaling management confidence, and aligns the director's interests with long-term shareholder value. It also represents a standard form of equity compensation that may lead to future dilution upon vesting.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• Vesting of the 27,000 Restricted Stock Units on the earlier of June 11, 2026, or the date of the annual shareholder meeting following the grant date, contingent on continued service.

Key Dates

Keywords

Puma Biotechnology, PBYI, SEC Form 4, Insider Trading, Restricted Stock Units, RSU, Director Stock Grant, Jay M. Moyes, Equity Compensation